Európska únia - slovinčina - EMA (European Medicines Agency)

actavis group ptc ehf - topotekan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastična sredstva - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5. topotecan v kombinaciji z cisplatin je indicirano za bolnike z karcinom materničnega vratu periodično po radioterapija in za bolnike z stadiju ivb bolezni. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.

Európska únia - slovinčina - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - narcolepsy - druga zdravila na živčnem sistemu - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.

Európska únia - slovinčina - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - abakavir, lamivudin - filmsko obložena tableta - abakavir 600 mg / 1 tableta; lamivudin 300 mg / 1 tableta - lamivudin in abakavir

Slovinsko - slovinčina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - abakavir, lamivudin - filmsko obložena tableta - abakavir 600 mg / 1 tableta; lamivudin 300 mg / 1 tableta - lamivudin in abakavir

Európska únia - slovinčina - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - velmanase alfa - alfa-mannosidosis - drugi zdravljene bolezni prebavil in presnove izdelki, - zdravljenje brez nevrološke manifestacije pri bolnikih z blago do zmerno alfa-mannosidosis.

Európska únia - slovinčina - EMA (European Medicines Agency)

orphelia pharma sas - klofarabin - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - zdravljenje akutno limfoblastno levkemijo, (vse), pri pediatričnih bolnikih, ki so ponovila ali so ognjevarni po prejemu vsaj dve predhodni režimi in če ni druge možnosti zdravljenja, predvidene za posledico trajno odgovor. varnost in učinkovitost sta bili ocenjeni pri študijah pri bolnikih ≤ 21 let pri začetni diagnozi.

Európska únia - slovinčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Európska únia - slovinčina - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatid - osteoporosis; osteoporosis, postmenopausal - kalcij homeostaza - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.